Nanomedicine for the treatment of musculoskeletal diseases

Ke Ren, Xin Wei, Lingli Zhang, Dong Wang

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

The human adult skeletal system is comprised of 206 bones, along with a network of ligaments, tendons and cartilage. In addition to providing locomotion, the skeletal tissues serve as attachment sites for muscles and as protection for vital soft tissue organs. They harbor hematopoietic tissues (bone marrow) and act as a reservoir for calcium and phosphorus. Just as with any other organ systems, many pathological conditions are associated with musculoskeletal tissues, such as osteoporosis, arthritis, impaired fracture healing, and bone cancers, etc. These diseases affect many people, especially the geriatric population, resulting in pain, stiffness, loss of body function and even mortality. The health-related quality of life in patients with musculoskeletal diseases is signifi cantly reduced, and the rising number of patients suffering from agerelated musculoskeletal diseases can become a signifi cant economic burden in an aging society. To address this issue, many clinical interventions, ranging from new therapeutic treatments to novel surgical procedures, have been developed. Due to the inherent nature of the musculoskeletal system and its clinical relevance, extensive work has been done in the development of nanomaterials scaffolding and the local delivery of functional agents to improve bone repair/regeneration, osseointegration with orthopedic implants and prevention or treatment of postoperative infections. This is a rather crowded fi eld with many high quality reviews being published (Tran and Webster. Wiley Interdiscip Rev Nanomed Nanobiotechnol 1(3): 336–351, 2009; Harvey et al. J Orthop Trauma 24(Suppl 1): S25–S30, 2010; Stylios et al. Injury 38(Suppl 1): S63–S74, 2007; Sato and Webster. Expert Rev Med Devices 1(1): 105–114, 2004; Webster and Ahn. Adv Biochem Eng Biotechnol 103: 275–308, 2007), which the readers are encouraged to explore. This chapter, however, will be mainly focused on several new directions in the fi eld, especially on the use of nanomaterials as carriers to target therapeutic agents to the musculoskeletal lesions after systemic administration. In contrast to the local nanomaterial depot approach, of which the material design and drug release/activation are somewhat arbitrary, the systemically administered carriers would “seek out” its target and deliver the drugs according to the pathological conditions present.

Original languageEnglish (US)
Title of host publicationMethods in Pharmacology and Toxicology
PublisherHumana Press Inc.
Pages389-412
Number of pages24
DOIs
StatePublished - Jan 1 2016

Publication series

NameMethods in Pharmacology and Toxicology
Volume39
ISSN (Print)1557-2153
ISSN (Electronic)1940-6053

Fingerprint

Musculoskeletal Diseases
Nanomedicine
Nanostructures
Osseointegration
Bone Neoplasms
Musculoskeletal System
Bone Regeneration
Fracture Healing
Wounds and Injuries
Therapeutics
Locomotion
Ligaments
Geriatrics
Tendons
Phosphorus
Osteoporosis
Arthritis
Cartilage
Orthopedics
Bone Marrow

Keywords

  • Arthritis
  • Bone anabolic agent
  • Bone cancer
  • Bone-targeting
  • ELVIS mechanism
  • Infl ammation
  • Musculoskeletal disease
  • Nanomedicine
  • Osteoporosis
  • Regenerative medicine

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Ren, K., Wei, X., Zhang, L., & Wang, D. (2016). Nanomedicine for the treatment of musculoskeletal diseases. In Methods in Pharmacology and Toxicology (pp. 389-412). (Methods in Pharmacology and Toxicology; Vol. 39). Humana Press Inc.. https://doi.org/10.1007/978-1-4939-3121-7_20

Nanomedicine for the treatment of musculoskeletal diseases. / Ren, Ke; Wei, Xin; Zhang, Lingli; Wang, Dong.

Methods in Pharmacology and Toxicology. Humana Press Inc., 2016. p. 389-412 (Methods in Pharmacology and Toxicology; Vol. 39).

Research output: Chapter in Book/Report/Conference proceedingChapter

Ren, K, Wei, X, Zhang, L & Wang, D 2016, Nanomedicine for the treatment of musculoskeletal diseases. in Methods in Pharmacology and Toxicology. Methods in Pharmacology and Toxicology, vol. 39, Humana Press Inc., pp. 389-412. https://doi.org/10.1007/978-1-4939-3121-7_20
Ren K, Wei X, Zhang L, Wang D. Nanomedicine for the treatment of musculoskeletal diseases. In Methods in Pharmacology and Toxicology. Humana Press Inc. 2016. p. 389-412. (Methods in Pharmacology and Toxicology). https://doi.org/10.1007/978-1-4939-3121-7_20
Ren, Ke ; Wei, Xin ; Zhang, Lingli ; Wang, Dong. / Nanomedicine for the treatment of musculoskeletal diseases. Methods in Pharmacology and Toxicology. Humana Press Inc., 2016. pp. 389-412 (Methods in Pharmacology and Toxicology).
@inbook{d2414d785f164c6db53c73cb11a9ebe2,
title = "Nanomedicine for the treatment of musculoskeletal diseases",
abstract = "The human adult skeletal system is comprised of 206 bones, along with a network of ligaments, tendons and cartilage. In addition to providing locomotion, the skeletal tissues serve as attachment sites for muscles and as protection for vital soft tissue organs. They harbor hematopoietic tissues (bone marrow) and act as a reservoir for calcium and phosphorus. Just as with any other organ systems, many pathological conditions are associated with musculoskeletal tissues, such as osteoporosis, arthritis, impaired fracture healing, and bone cancers, etc. These diseases affect many people, especially the geriatric population, resulting in pain, stiffness, loss of body function and even mortality. The health-related quality of life in patients with musculoskeletal diseases is signifi cantly reduced, and the rising number of patients suffering from agerelated musculoskeletal diseases can become a signifi cant economic burden in an aging society. To address this issue, many clinical interventions, ranging from new therapeutic treatments to novel surgical procedures, have been developed. Due to the inherent nature of the musculoskeletal system and its clinical relevance, extensive work has been done in the development of nanomaterials scaffolding and the local delivery of functional agents to improve bone repair/regeneration, osseointegration with orthopedic implants and prevention or treatment of postoperative infections. This is a rather crowded fi eld with many high quality reviews being published (Tran and Webster. Wiley Interdiscip Rev Nanomed Nanobiotechnol 1(3): 336–351, 2009; Harvey et al. J Orthop Trauma 24(Suppl 1): S25–S30, 2010; Stylios et al. Injury 38(Suppl 1): S63–S74, 2007; Sato and Webster. Expert Rev Med Devices 1(1): 105–114, 2004; Webster and Ahn. Adv Biochem Eng Biotechnol 103: 275–308, 2007), which the readers are encouraged to explore. This chapter, however, will be mainly focused on several new directions in the fi eld, especially on the use of nanomaterials as carriers to target therapeutic agents to the musculoskeletal lesions after systemic administration. In contrast to the local nanomaterial depot approach, of which the material design and drug release/activation are somewhat arbitrary, the systemically administered carriers would “seek out” its target and deliver the drugs according to the pathological conditions present.",
keywords = "Arthritis, Bone anabolic agent, Bone cancer, Bone-targeting, ELVIS mechanism, Infl ammation, Musculoskeletal disease, Nanomedicine, Osteoporosis, Regenerative medicine",
author = "Ke Ren and Xin Wei and Lingli Zhang and Dong Wang",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-1-4939-3121-7_20",
language = "English (US)",
series = "Methods in Pharmacology and Toxicology",
publisher = "Humana Press Inc.",
pages = "389--412",
booktitle = "Methods in Pharmacology and Toxicology",

}

TY - CHAP

T1 - Nanomedicine for the treatment of musculoskeletal diseases

AU - Ren, Ke

AU - Wei, Xin

AU - Zhang, Lingli

AU - Wang, Dong

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The human adult skeletal system is comprised of 206 bones, along with a network of ligaments, tendons and cartilage. In addition to providing locomotion, the skeletal tissues serve as attachment sites for muscles and as protection for vital soft tissue organs. They harbor hematopoietic tissues (bone marrow) and act as a reservoir for calcium and phosphorus. Just as with any other organ systems, many pathological conditions are associated with musculoskeletal tissues, such as osteoporosis, arthritis, impaired fracture healing, and bone cancers, etc. These diseases affect many people, especially the geriatric population, resulting in pain, stiffness, loss of body function and even mortality. The health-related quality of life in patients with musculoskeletal diseases is signifi cantly reduced, and the rising number of patients suffering from agerelated musculoskeletal diseases can become a signifi cant economic burden in an aging society. To address this issue, many clinical interventions, ranging from new therapeutic treatments to novel surgical procedures, have been developed. Due to the inherent nature of the musculoskeletal system and its clinical relevance, extensive work has been done in the development of nanomaterials scaffolding and the local delivery of functional agents to improve bone repair/regeneration, osseointegration with orthopedic implants and prevention or treatment of postoperative infections. This is a rather crowded fi eld with many high quality reviews being published (Tran and Webster. Wiley Interdiscip Rev Nanomed Nanobiotechnol 1(3): 336–351, 2009; Harvey et al. J Orthop Trauma 24(Suppl 1): S25–S30, 2010; Stylios et al. Injury 38(Suppl 1): S63–S74, 2007; Sato and Webster. Expert Rev Med Devices 1(1): 105–114, 2004; Webster and Ahn. Adv Biochem Eng Biotechnol 103: 275–308, 2007), which the readers are encouraged to explore. This chapter, however, will be mainly focused on several new directions in the fi eld, especially on the use of nanomaterials as carriers to target therapeutic agents to the musculoskeletal lesions after systemic administration. In contrast to the local nanomaterial depot approach, of which the material design and drug release/activation are somewhat arbitrary, the systemically administered carriers would “seek out” its target and deliver the drugs according to the pathological conditions present.

AB - The human adult skeletal system is comprised of 206 bones, along with a network of ligaments, tendons and cartilage. In addition to providing locomotion, the skeletal tissues serve as attachment sites for muscles and as protection for vital soft tissue organs. They harbor hematopoietic tissues (bone marrow) and act as a reservoir for calcium and phosphorus. Just as with any other organ systems, many pathological conditions are associated with musculoskeletal tissues, such as osteoporosis, arthritis, impaired fracture healing, and bone cancers, etc. These diseases affect many people, especially the geriatric population, resulting in pain, stiffness, loss of body function and even mortality. The health-related quality of life in patients with musculoskeletal diseases is signifi cantly reduced, and the rising number of patients suffering from agerelated musculoskeletal diseases can become a signifi cant economic burden in an aging society. To address this issue, many clinical interventions, ranging from new therapeutic treatments to novel surgical procedures, have been developed. Due to the inherent nature of the musculoskeletal system and its clinical relevance, extensive work has been done in the development of nanomaterials scaffolding and the local delivery of functional agents to improve bone repair/regeneration, osseointegration with orthopedic implants and prevention or treatment of postoperative infections. This is a rather crowded fi eld with many high quality reviews being published (Tran and Webster. Wiley Interdiscip Rev Nanomed Nanobiotechnol 1(3): 336–351, 2009; Harvey et al. J Orthop Trauma 24(Suppl 1): S25–S30, 2010; Stylios et al. Injury 38(Suppl 1): S63–S74, 2007; Sato and Webster. Expert Rev Med Devices 1(1): 105–114, 2004; Webster and Ahn. Adv Biochem Eng Biotechnol 103: 275–308, 2007), which the readers are encouraged to explore. This chapter, however, will be mainly focused on several new directions in the fi eld, especially on the use of nanomaterials as carriers to target therapeutic agents to the musculoskeletal lesions after systemic administration. In contrast to the local nanomaterial depot approach, of which the material design and drug release/activation are somewhat arbitrary, the systemically administered carriers would “seek out” its target and deliver the drugs according to the pathological conditions present.

KW - Arthritis

KW - Bone anabolic agent

KW - Bone cancer

KW - Bone-targeting

KW - ELVIS mechanism

KW - Infl ammation

KW - Musculoskeletal disease

KW - Nanomedicine

KW - Osteoporosis

KW - Regenerative medicine

UR - http://www.scopus.com/inward/record.url?scp=84946882095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946882095&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-3121-7_20

DO - 10.1007/978-1-4939-3121-7_20

M3 - Chapter

AN - SCOPUS:84946882095

T3 - Methods in Pharmacology and Toxicology

SP - 389

EP - 412

BT - Methods in Pharmacology and Toxicology

PB - Humana Press Inc.

ER -